coteauBeta Get App

STAA

STAAR Surgical Company
$22.61
+0.53% Oct 23 close
Health CareS&P 600 CompareTechnicals
1M3M6M1Y2Y
-35%-18%-1%+17%+34%Oct 2025Oct 2026Apr 202652w high $33.3452w low $16.10
STAASPY
1W
+6.3%
1M
+14.2%
3M
-3.3%
6M
-11.9%
YTD
-2.1%
1Y
-16.1%

Live chart

Loading live chart…

What they do

STAAR Surgical Company designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors.

Healthcare · Medical Instruments & Supplies

For information only · Important disclosures

Grades vs sector

Momentum
20th percentile in sector
D
12-1 return: -12.6%
Percentile within its GICS sector across the S&P 1500.
Growth
97th percentile in sector
A+
Revenue growth (YoY): +111.0%
Percentile within its GICS sector across the S&P 1500.
Value
41st percentile in sector
C
Forward E/P: 5.2% · EBITDA/EV: 5.4%
Percentile within its GICS sector across the S&P 1500.
Profitability
26th percentile in sector
D+
Profit margin: +1.1% · Return on equity: +1.1%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Otis Worldwide Corporation (NYSE: OTIS)
PR Newswire · Oct 21

Key stats

52-week range$16.10 – $33.34
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

Earnings

STAA earningsNext report in 12 days
Next report · quarter Sep 2026
Wed Nov 4, 2026After the close
EPS consensus$0.17 range $0.06–$0.24
Revenue consensus$78.7M 10 analysts
Last 4 quarters · EPS vs estimate
Aug 12, 2026$0.25est $0.23+9.7%Above estimates
May 13, 2026$0.29est $0.08+266.8%Above estimates
Mar 3, 2026$0.01est $0.17−95.2%Below estimates
Nov 5, 2025$0.47est $0.28+68.3%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 18:22:27 ET
24-1025-0225-0525-0825-1126-0326-0526-08-1.000.47
EstimateActual (beat)Actual (miss)
Rating changes
Upgrade
2026-09-29 · Stifel upgraded STAA from Hold to Buy
Reiterated
2026-09-22 · Jefferies reiterated Buy on STAA
Reiterated
2026-08-17 · Stifel reiterated Hold on STAA
Reiterated
2026-08-13 · UBS reiterated Sell on STAA
Reiterated
2026-08-13 · Jefferies reiterated Buy on STAA
Reiterated
2026-08-13 · Wedbush reiterated Outperform on STAA

Third-party analyst actions, not Coteau's views. All rating changes

Insider trades
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-21 18:22:27 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026